DTIL Financials

Income Statement
MetricQ3 2026Q1 2027Q4 2025Q3 2025Q1 2026
Revenue
0
0
-100.0%
34.2M
+263007.7%
13.0K
-27.8%
18.0K
Cost of Revenue
0
0
0
0
0
Gross Profit
0
0
-100.0%
34.2M
+263007.7%
13.0K
-27.8%
18.0K
Operating Expenses
20.4M
+6.6%
19.2M
-11.7%
21.7M
+4.9%
20.7M
-5.5%
21.9M
R&D
12.7M
+2.8%
12.4M
-14.3%
14.5M
+8.3%
13.4M
+4.6%
12.8M
SG&A
7.7M
+13.5%
6.8M
-6.4%
7.2M
-1.3%
7.3M
-19.7%
9.1M
Operating Income
-20428000
-6.6%
-19161000
-253.2%
12.5M
+160.5%
-20667000
+5.5%
-21877000
EBITDA
-20428000
-6.6%
-19161000
-249.1%
12.9M
+162.2%
-20667000
+5.5%
-21877000
Net Income
-7586000
+76.8%
-32652000
-262.2%
20.1M
+192.5%
-21772000
+7.4%
-23520000
EPS (Basic)
$-0.28
+77.8%
$-1.26
-220.0%
$1.05
+157.1%
$-1.84
+13.6%
$-2.13
EPS (Diluted)
$-0.28
+77.8%
$-1.26
-220.0%
$1.05
+157.1%
$-1.84
+13.6%
$-2.13
Shares (Diluted)
27.4M
+6.1%
25.9M
+35.0%
19.1M
+62.0%
11.8M
+7.0%
11.0M
Precision BioSciences (DTIL) — Financials